Analyst Price Targets — RPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 1:39 pm | — | Goldman Sachs | $66.00 | $57.02 | TheFly | Royalty Pharma price target raised to $66 from $59 at Goldman Sachs |
| August 6, 2026 11:46 am | — | Morgan Stanley | $65.00 | $57.75 | TheFly | Royalty Pharma price target raised to $65 from $64 at Morgan Stanley |
| April 21, 2026 11:14 am | Ashwani Verma | UBS | $57.00 | $49.30 | TheFly | Royalty Pharma price target raised to $57 from $51 at UBS |
| April 10, 2026 12:56 pm | Terence Flynn | Morgan Stanley | $63.00 | $47.98 | TheFly | Royalty Pharma price target raised to $63 from $61 at Morgan Stanley |
| February 27, 2026 6:43 pm | — | Seaport Global | $50.00 | $46.21 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen |
| February 12, 2026 1:14 pm | Terence Flynn | Morgan Stanley | $61.00 | $44.71 | TheFly | Royalty Pharma price target raised to $61 from $56 at Morgan Stanley |
| January 30, 2026 9:40 am | Ashwani Verma | UBS | $49.00 | $40.86 | TheFly | Royalty Pharma upgraded to Buy from Neutral at UBS |
| December 11, 2025 3:12 pm | — | Leerink Partners | $45.00 | $38.22 | StreetInsider | Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' |
| September 30, 2025 9:10 am | — | Goldman Sachs | $42.00 | $35.25 | TheFly | Royalty Pharma initiated with a Buy at Goldman Sachs |
| July 10, 2025 12:34 pm | Terence Flynn | Morgan Stanley | $54.00 | $36.14 | TheFly | Royalty Pharma price target raised to $54 from $51 at Morgan Stanley |
Latest News for RPRX
Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive…
Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth…
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RPRX.
U.S. House Trading
No House trades found for RPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.